Teva Pharmaceuticals

This #WorldBipolarDay, we recognize the profound implications of living with bipolar I disorder (BD-I), as people face the physical, mental and emotional burdens of this complex condition. We are committed to understanding and walking alongside patients as they navigate their unique paths to treatment and wellbeing. Learn more about our dedication to those living with complex mental health conditions, including BD-I, and our ongoing efforts to foster a healthier future: https://ow.ly/LC9J50YzVnf #WeAreAllInForBetterHealth #TogetherWeCanHelpPatients #TevaPharm

Teva’s expanding biosimilars portfolio continues to advance. Our biosimilar to treat a variety of bone conditions has just received U.S. FDA approval, and our proposed biosimilar candidate to treat a range of allergic diseases and atopic conditions has been accepted for review by both the #FDA and European Medicines Agency (#EMA). Together, these milestones mark an important step forward in our efforts to expand access to high-quality biologics medicines and increase treatment options for patients, reflecting the acceleration of our #biosimilars portfolio and the strength of our global development and commercialization capabilities. Check out our press release to learn more: https://ow.ly/Pfuo50YABkC #Biosimilars #PatientAccess #TevaPharm #WeAreAllInForBetterHealth

As a physician, Eric A. Hughes, MD, PhD, Teva’s EVP of Global R&D and Chief Medical Officer, sees patient access to effective treatments as a critical focus. That patient-first mindset is reflected in Teva’s pipeline, which includes investigational therapies in autoimmune conditions, respiratory diseases, and neurological disorders – targeting areas where new solutions are urgently needed. Read how Eric and Chris Fox, EVP US Commercial, look at innovation across Teva’s portfolio: https://ow.ly/897Z50YwjYS

☀️ U březnového Týdne pohybu pro roztroušenou sklerózu opět nemohl chybět náš Teva tým! Nadační fond Impuls, který akci každoročně pořádá, připomíná lidem žijícím s touto nemocí, že pravidelné cvičení přispívá k úspěšné léčbě RS. 🏋️♀️ Náš firemní tým si proto vyzkoušel pestrou škálu cvičení. A připomněli jsme si, že i dobré vztahy spolu navzájem přispívají ke zvládání této chronické nemoci i na cestě k vyléčení. 🍽️ Součástí programu bylo i edukační video na téma zdravé stravování a změna životního stylu při diagnóze RS - všechno tohle pacientům pomáhá. Před pacienty s chronickými onemocněními máme velký respekt. Ti, kdo i se svojí nemocí žijí aktivním životem, si zaslouží náš obdiv. Děláme všechno pro to, aby mohli žít plnohodnotný život. 🙏 Děkujeme za krásné chvíle a obohacující setkání. Jedině vzájemnou podporou můžeme náš život dělat lepším. #Teva #TevaCesko #TevaCZ #ChronickeOnemocneni #RoztrousenaSkleroza

Most people have never heard of Multiple System Atrophy (MSA), yet for those diagnosed, it changes everything. MSA is a rare, rapidly progressive brain disorder that can resemble Parkinson’s disease, but it advances more aggressively and does not respond well to Parkinson’s medications. There is no cure yet, and treatments focus on easing symptoms and improving quality of life. Building on a legacy of innovation in neuroscience, Teva is committed to advancing research and developing therapies for neurological conditions like MSA. Last September, the U.S. FDA granted Fast Track designation to our potential treatment for MSA, reinforcing our commitment to developing new options for patients living with complex neurological diseases. Explore more about MSA and ongoing research: https://ow.ly/xVKj50Yv8xZ

ICYMI: This year, Teva is partnering with actor and advocate Will Forte, along with his brother-in-law, Doug Modling, to share their personal story with #HuntingtonsDisease (HD). The pair recently sat down for an interview with The Healthy, where they opened up about what has inspired and motivated Doug to face his diagnosis, and how he has found support from his brother-in-law and the larger HD community. We’re proud to help share Will and Doug’s story, because their story is not unlike the ~41,000 Americans living with this complex and often overlooked neurological condition. Together, we hope that these open and honest conversations, as well as sharing resources via our Honestly HD platform, can play a part in helping others on their HD journey. Check out their full interview here: https://ow.ly/gKi050YtmmC #TevaPharm

Since joining Teva in 2024, I’ve experienced firsthand the strength of our inclusive culture and the genuine support that comes from working alongside colleagues who truly value diversity. Each day, I see the passion and dedication that our people bring to creating a welcoming environment, and it inspires me to keep pushing for progress. As a company, we are committed to being a truly inclusive place where we are all in for better health. On International Women’s Day, as I do every day, I want to recognize the contribution of the women at Teva and the important role they play in shaping our business, our teams, and our leadership.   Together, we will continue to evolve our Inclusion & Diversity approach -- not as an initiative, but as a genuine promise to each other. We want to make sure everyone has fair access to opportunity, and that growth and success are earned through hard work, integrity, and shared achievement. I am grateful for the diverse perspectives across backgrounds, experiences, thinking styles, and generations that help us learn, grow, and perform at our best. Thank you to everyone who makes Teva a place where inclusion isn’t just a goal, but a lived reality. #InternationalWomensDay #Leadership #InclusionAndDiversity #Culture

It's International Women's Day, and this year’s theme is “Give to Gain” – how generosity, collaboration, and investing in women create systemic change. But what does it really mean to Give to Gain? It's not about grand gestures. It's about the daily work of collaboration: learning from failure, seeking out the people who hold pieces of the puzzle you're missing, finding shared language across differences, extending grace to yourself and others, and choosing to stay and invest where your work matters. At Teva, we strive to show up for women and embrace diversity at many moments throughout the year, since the real impact comes from those everyday actions that strengthen our teams and our culture.  Navdeep, Magdalena, Ivana, Beryl and Yuliyana show us how we are all in – through real work, real challenges, and real leadership. Swipe through to hear their stories 👉 #IWD2026 #GiveToGain #WomenOfTeva

Today we announced a $400M strategic funding agreement with Blackstone Life Sciences to support the continued development of duvakitug, an investigational TL1A antibody currently in Phase 3 studies for the treatment of ulcerative colitis and Crohn’s disease. As our head of Business Development Evan Lippman shared, this agreement enables us to advance a priority asset while maintaining a disciplined, capital‑efficient approach to growth. This is the power of strategic collaborations to accelerate meaningful innovation for patients. Read the full announcement here: https://ow.ly/7aXj50YoT0J #TevaPharm #PivotToGrowth #Innovation #IBD

What sets Teva R&D apart? Our R&D teams - across innovative medicines, generics, and biosimilars - are moving ideas from the lab to real-world impact faster than ever. Because, as one of our R&D leaders reminds us, patients are waiting. Watch this video and learn more about our bold thinking, innovative spirit, and purpose-driven culture. Curiosity. Talent. Momentum. This is Teva R&D. #TevaPharm #TevaRnDThePlaceToBe #WeAreAllInForBetterHealth